Bio News
Novo Nordisk has discontinued development of a single-formulation version of the GLP-1/amylin combination drug CagriSema but is maintaining its plan for a launch in early 2027. The treatment, which combines semaglutide and cagrilintide, is expected to be supplied through a dual-chamber system, with U.S. Food and Drug Administration (FDA) approval anticipated in the fourth quarter of this year. Following CagriSema, Novo Nordisk plans to launch the dual agonist zenagamtide, which has entered Phase 3 clinical trials, to strengthen its position in the obesity treatment market.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
